Massive Bio, Inc.
Massive Bio is an AI-driven health-tech platform that connects cancer patients to clinical trials globally, aiming to improve access to innovative therapies by working with healthcare providers and pharmaceutical companies. The company focuses on expanding its impact through its proprietary AI platform and empowering clinicians to deliver personalized care.
Massive Bio is a healthcare technology company that uses AI-driven cancer analysis and clinical trial matching to connect oncology patients with appropriate investigational therapies. Their platform integrates clinical and genomic data to identify and prioritize trial matches, streamline referrals, and simplify enrollment workflows for hospitals, cancer centers, and life‑science sponsors. The company also offers patient navigation, molecular tumor board support, and site activation services to improve the patient experience and boost trial accrual. Massive Bio works with health systems, biopharma, and CRO partners to accelerate precision oncology research and broaden access to clinical trials.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Massive Bio, Inc..
13% above the average for this role
Principal Scientist/Associate Director/Director, Clinical Science
Acrivon Therapeutics
Medical Oncology Advanced Practice Provider
Munson Healthcare
Sr Therapeutic Specialist, Oncology - Seattle
Gilead Sciences
Oncology Advanced Practice Provider
The University of New Mexico
Oncology Advanced Practice Provider
The University of New Mexico
Medical Director of Neuro-Oncology - Saint Luke's - Kansas City
St. Luke's Hospital